CEFDINIR IN RESPIRATORY TRACT INFECTION

• Published in: CHEMOTHERAPY Vol. 37; no. Supplement2; pp. 257 - 262
• Main Authors: OSAKI, YOSHINOBU, NAKANO, HITOSHI, ONODERA, SOUKICHI, SASAKI, NOBUHIRO, AKIBA, YUJI, OSANAI, SHINOBU, KAWABE, JUNICHI, MATSUMOTO, HIROYUKI, ISHIDA, SAKAE, FUJIKANE, TOSHIAKI
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1989; 公益社団法人 日本化学療法学会
• Subjects: Cefdinir; 呼吸器感染症; 肺炎; 臨床的検討
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.37.Supplement2_257

We performed clinical studies on cefdinir (CFDN), a new oral cephalosporin, with the following results. 1. CFDN was administered to 17 patients with respiratory tract infections: 15 with pneumonia, 1 with secondary infection with bronchiectasis and 1 with acute tonsillitis. Clinical efficacy was excellent in 7, good in 5, fair in 1 and poor in 3, with an efficacy rate of 75%. 2. As to side effects, loose stools were noted in one patient.In laboratory findings, an elevation of transaminase due to CFDN was noted in 3 of 17 patients. 3. We considered CFDN to be effective for primary pneumonia in doses of 100mg or 200mg t. i. d.